Skip to main content

Advertisement

Table 3 Objective response rate by crizotinib treatment

From: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Response No. of Patients (%) P-value
ALK + c-Met-
(n = 101)
ALK + c-Met+
(n = 15)
Complete response, n (%) 0(0.0%) 0(0.0%)  
Partial response, n (%) 60(59.4%) 13(86.7%)  
Stable disease, n (%) 25(24.8%) 2(13.3%)  
Progressive disease, n (%) 16(15.8%) 0(0.0%)  
ORR, % 59.4% 86.7% 0.041
DCR, % 84.2% 100% 0.126
  1. Abbreviations: ALK anaplastic lymphoma kinase, c-Met cellular-mesenchymal-epithelial transition, ALK + c-Met+ patients with ALK rearrangement and c-Met overexpression positive, ALK + c-Met- patients with ALK rearrangement and c-Met overexpression negative